Yang Sun, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sun’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A96850 · Current
Licensed to practise in California · since 2006 · expires 2028-06-30 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$114,552
Medicare paid this office $114,552 for 467 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 293 | $34,523 | $79 |
| Removal of cataract with insertion of prosthetic lens | 45 | $32,864 | $522 |
| Complex removal of cataract with insertion of prosthetic lens | 16 | $12,182 | $717 |
| Short return visit (20+ min) | 186 | $11,020 | $47 |
| New patient visit (45+ min) | 76 | $7,477 | $98 |
See all 12 services
| Return visit (30+ min) | 293 | $34,523 | $79 |
| Removal of cataract with insertion of prosthetic lens | 45 | $32,864 | $522 |
| Complex removal of cataract with insertion of prosthetic lens | 16 | $12,182 | $717 |
| Short return visit (20+ min) | 186 | $11,020 | $47 |
| New patient visit (45+ min) | 76 | $7,477 | $98 |
| Exam of visual field with extended testing | 198 | $5,114 | $23 |
| Imaging of optic nerve | 220 | $4,073 | $17 |
| Measurement of corneal curvature and depth of eye | 39 | $1,243 | $28 |
| New patient visit (30+ min) | 18 | $1,171 | $65 |
| Imaging of retina | 50 | $1,067 | $21 |
| Ct scan of cornea | 14 | $289 | $18 |
| Photography of the retina | 13 | $210 | $16 |
Procedures Medicare counted
| Cataract surgery | 69 | More than 69% of doctors who do this |
Who their Medicare patients are
467 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 15% · Women 54% · Also on Medicaid 28% · Health risk score 1.10. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 65% · Diabetes 28% · Coronary heart disease 23% · Chronic kidney disease 18% · Depression 14% · Cancer 13% · Atrial fibrillation 12% · Heart failure 10% · Stroke 7% · COPD 6% · Dementia 4%.
The office billed $648,106, Medicare allowed $156,960 and paid $114,552; for 1,462 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 467 | 1,462 | 75 | 1.10 | $648,106 | $114,552 |
| 2023 | 358 | 1,122 | 75 | 1.10 | $294,087 | $73,926 |
| 2022 | 279 | 865 | 75 | 1.08 | $292,295 | $69,194 |
| 2021 | 240 | 772 | 75 | 1.05 | $286,936 | $64,942 |
| 2020 | 149 | 412 | 74 | 1.20 | $118,268 | $27,420 |
| 2019 | 149 | 453 | 76 | 1.25 | $177,366 | $36,133 |
| 2018 | 117 | 359 | 74 | 1.29 | $116,199 | $26,950 |
| 2017 | 83 | 157 | 73 | 1.31 | $64,783 | $13,690 |
| 2016 | 131 | 235 | 69 | 1.79 | $92,193 | $21,176 |
| 2015 | 125 | 245 | 68 | 1.43 | $97,386 | $24,710 |
| 2014 | 129 | 285 | 68 | 1.68 | $107,219 | $29,553 |
| 2013 | 118 | 231 | 68 | 1.44 | $64,000 | $19,074 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 236 | $29,227 | $78 |
| Removal of cataract with insertion of prosthetic lens | 17 | $13,580 | $522 |
| Short return visit (20+ min) | 175 | $11,980 | $51 |
| New patient visit (45+ min) | 47 | $5,101 | $109 |
| Exam of visual field with extended testing | 179 | $4,813 | $24 |
| Imaging of optic nerve | 155 | $2,884 | $19 |
| New patient visit (30+ min) | 11 | $682 | $62 |
| Measurement of corneal curvature and depth of eye | 17 | $527 | $29 |
| Imaging of retina | 16 | $406 | $24 |
| Photography of the retina | 14 | $261 | $17 |
2022: 7 services
| Return visit (30+ min) | 234 | $33,561 | $76 |
| Removal of cataract with insertion of prosthetic lens | 18 | $11,325 | $515 |
| New patient visit (45+ min) | 37 | $4,100 | $111 |
| Short return visit (20+ min) | 46 | $2,922 | $53 |
| Exam of visual field with extended testing | 112 | $2,774 | $23 |
| Imaging of optic nerve | 124 | $2,328 | $19 |
| Measurement of corneal curvature and depth of eye | 20 | $582 | $29 |
2021: 8 services
| Return visit (30+ min) | 172 | $24,660 | $78 |
| Removal of cataract with insertion of prosthetic lens | 17 | $13,578 | $522 |
| New patient visit (45+ min) | 56 | $6,005 | $107 |
| Short return visit (20+ min) | 54 | $3,502 | $58 |
| Imaging of optic nerve | 146 | $2,602 | $17 |
| Exam of visual field with extended testing | 78 | $1,919 | $23 |
| Measurement of corneal curvature and depth of eye | 23 | $653 | $28 |
| Imaging of retina | 13 | $295 | $23 |
2020: 5 services
| Return visit (30+ min) | 123 | $12,591 | $62 |
| New patient visit (45+ min) | 22 | $1,981 | $90 |
| Imaging of optic nerve | 66 | $1,259 | $19 |
| Exam of visual field with extended testing | 49 | $1,110 | $22 |
| Short return visit (20+ min) | 12 | $659 | $47 |
2019: 5 services
| Return visit (30+ min) | 108 | $12,586 | $61 |
| New patient visit (45+ min) | 40 | $3,989 | $100 |
| Exam of visual field with extended testing | 53 | $1,333 | $23 |
| Imaging of optic nerve | 65 | $1,172 | $18 |
| Short return visit (20+ min) | 19 | $964 | $42 |
2018: 6 services
| Return visit (30+ min) | 85 | $10,173 | $66 |
| New patient visit (45+ min) | 32 | $3,248 | $102 |
| Exam of visual field with extended testing | 55 | $1,461 | $24 |
| Imaging of optic nerve | 56 | $1,078 | $19 |
| New patient visit (30+ min) | 11 | $678 | $62 |
| Short return visit (20+ min) | 13 | $603 | $40 |
2017: 6 services
| Return visit (30+ min) | 40 | $3,668 | $69 |
| New patient visit (45+ min) | 11 | $1,248 | $113 |
| New patient visit (30+ min) | 12 | $815 | $68 |
| Short return visit (20+ min) | 14 | $456 | $33 |
| Exam of visual field with extended testing | 17 | $443 | $26 |
| Imaging of optic nerve | 17 | $331 | $19 |
2016: 5 services
| Short return visit (20+ min) | 77 | $3,051 | $34 |
| Return visit (30+ min) | 31 | $1,947 | $54 |
| Return visit (30+ min) | 11 | $715 | $60 |
| Exam of visual field with extended testing | 24 | $472 | $20 |
| Imaging of optic nerve | 13 | $257 | $20 |
2015: 3 services
| Return visit (30+ min) | 42 | $3,255 | $53 |
| Short return visit (20+ min) | 77 | $3,244 | $33 |
| Exam of visual field with extended testing | 23 | $425 | $18 |
2014: 5 services
| Short return visit (20+ min) | 98 | $4,625 | $34 |
| Laser repair to improve eye fluid flow | 12 | $3,030 | $233 |
| Return visit (30+ min) | 21 | $1,806 | $56 |
| Short return visit | 12 | $286 | $19 |
| Exam of visual field with extended testing | 14 | $284 | $20 |
2013: 3 services
| Short return visit (20+ min) | 79 | $3,994 | $35 |
| Return visit (30+ min) | 34 | $1,796 | $50 |
| Exam of visual field with extended testing | 19 | $383 | $19 |
Medicaid work
$4,277 in 2024
Medicaid paid $4,277 for 102 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 77 | $3,927 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 25 | $351 |
| 2024 | 102 | 2 | 27 | $4,277 |
| 2023 | 259 | 4 | 22 | $6,332 |
| 2022 | 187 | 1 | 25 | $6,111 |
| 2021 | 85 | 1 | 17 | $2,931 |
| 2020 | 45 | 1 | 17 | $1,491 |
| 2019 | 78 | 1 | 19 | $2,212 |
| 2018 | 30 | 1 | 15 | $835 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 162 | $4,528 |
| Short return visit (20+ min) | 44 | $943 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 28 | $445 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 25 | $416 |
2022
| Return visit (30+ min) | 187 | $6,111 |
2021
| Return visit (30+ min) | 85 | $2,931 |
2020
| Return visit (30+ min) | 45 | $1,491 |
2019
| Return visit (30+ min) | 78 | $2,212 |
2018
| Return visit (30+ min) | 30 | $835 |
Drugs they prescribed that Part D paid
$107,709
Pharmacies billed $107,709 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,632) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
858 generic and 774 brand-name prescriptions · $107,709 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rhopressa | 37 | $17,449 | $472 |
| Brimonidine | 168 | $8,506 | $51 |
| Lumigan | 28 | $8,483 | $303 |
| Brinzolamide | 38 | $7,639 | $201 |
| Rocklatan | 19 | $7,535 | $397 |
See all 18 drugs
| Rhopressa | 37 | $17,449 | $472 |
| Brimonidine | 168 | $8,506 | $51 |
| Lumigan | 28 | $8,483 | $303 |
| Brinzolamide | 38 | $7,639 | $201 |
| Rocklatan | 19 | $7,535 | $397 |
| Latanoprost | 691 | $4,899 | $7 |
| Betimol | 17 | $4,132 | $243 |
| Simbrinza | 12 | $3,463 | $289 |
| Brimonidine Tartrate-Timolol | 13 | $2,852 | $219 |
| Dorzolamide-Timolol | 161 | $2,760 | $17 |
| Travoprost | 23 | $2,561 | $111 |
| Dorzolamide-Timolol | 13 | $2,467 | $190 |
| Prednisolone Acetate | 43 | $1,899 | $44 |
| Pilocarpine | 26 | $1,266 | $49 |
| Acetazolamide | 21 | $1,113 | $53 |
| Timolol Maleate | 145 | $1,018 | $7 |
| Dorzolamide | 51 | $831 | $16 |
| Erythromycin | 41 | $389 | $9 |
Year by year
| 2024 | 1,632 | 299 | 0% (0) | 47% | $107,709 |
| 2023 | 1,279 | 247 | 0% (0) | 40% | $84,718 |
| 2022 | 1,058 | 201 | 0% (0) | 38% | $63,752 |
| 2021 | 1,026 | 195 | 0% (0) | 41% | $76,282 |
| 2020 | 659 | 120 | 0% (0) | 42% | $60,722 |
| 2019 | 593 | 91 | 0% (0) | 38% | $60,473 |
| 2018 | 393 | 78 | 0% (0) | 41% | $31,985 |
| 2017 | 217 | 54 | 0% (0) | 31% | $16,881 |
| 2016 | 283 | 51 | None | 37% | $21,475 |
| 2015 | 266 | 50 | None | 45% | $22,679 |
| 2014 | 174 | 37 | 0% (0) | None | $11,744 |
| 2013 | 83 | 24 | 0% (0) | None | $6,427 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Rhopressa | 25 | $10,621 | $425 |
| Brimonidine | 138 | $8,928 | $65 |
| Lumigan | 18 | $6,951 | $386 |
| Latanoprost | 517 | $6,290 | $12 |
| Travoprost | 16 | $4,962 | $310 |
| Timolol Maleate | 167 | $4,123 | $25 |
| Dorzolamide-Timolol | 110 | $3,120 | $28 |
| Dorzolamide-Timolol | 17 | $2,255 | $133 |
| Methazolamide | 12 | $1,504 | $125 |
| Dorzolamide | 59 | $1,305 | $22 |
| Prednisolone Acetate | 23 | $1,145 | $50 |
| Acetazolamide | 14 | $885 | $63 |
| Pilocarpine | 15 | $823 | $55 |
| Erythromycin | 40 | $435 | $11 |
2022: 13 drugs
| Latanoprost | 403 | $5,964 | $15 |
| Brimonidine | 122 | $5,744 | $47 |
| Rhopressa | 17 | $5,266 | $310 |
| Travoprost | 21 | $3,829 | $182 |
| Lumigan | 12 | $3,382 | $282 |
| Methazolamide | 16 | $3,234 | $202 |
| Dorzolamide-Timolol | 88 | $2,543 | $29 |
| Combigan | 11 | $2,428 | $221 |
| Timolol Maleate | 132 | $2,202 | $17 |
| Dorzolamide | 54 | $1,234 | $23 |
| Prednisolone Acetate | 18 | $1,018 | $57 |
| Acetazolamide | 22 | $992 | $45 |
| Erythromycin | 34 | $360 | $11 |
2021: 12 drugs
| Restasis | 18 | $13,181 | $732 |
| Lumigan | 24 | $7,775 | $324 |
| Latanoprost | 384 | $7,023 | $18 |
| Rhopressa | 14 | $4,773 | $341 |
| Brimonidine | 106 | $4,759 | $45 |
| Timolol Maleate | 108 | $3,671 | $34 |
| Dorzolamide-Timolol | 81 | $3,108 | $38 |
| Acetazolamide | 40 | $2,501 | $63 |
| Simbrinza | 11 | $2,129 | $194 |
| Prednisolone Acetate | 19 | $1,268 | $67 |
| Dorzolamide | 39 | $952 | $24 |
| Erythromycin | 36 | $452 | $13 |
2020: 13 drugs
| Vyzulta | 26 | $7,442 | $286 |
| Lumigan | 19 | $6,204 | $327 |
| Rhopressa | 14 | $6,112 | $437 |
| Azopt | 15 | $5,276 | $352 |
| Latanoprost | 229 | $4,108 | $18 |
| Betimol | 15 | $3,625 | $242 |
| Dorzolamide-Timolol | 68 | $3,498 | $51 |
| Brimonidine | 47 | $2,723 | $58 |
| Acetazolamide | 24 | $2,240 | $93 |
| Timolol Maleate | 66 | $2,229 | $34 |
| Prednisolone Acetate | 13 | $717 | $55 |
| Dorzolamide | 18 | $634 | $35 |
| Erythromycin | 26 | $332 | $13 |
2019: 12 drugs
| Brimonidine | 64 | $8,926 | $139 |
| Azopt | 23 | $8,395 | $365 |
| Rhopressa | 21 | $7,144 | $340 |
| Vyzulta | 20 | $6,583 | $329 |
| Combigan | 15 | $5,752 | $383 |
| Travatan Z | 15 | $4,120 | $275 |
| Latanoprost | 214 | $2,974 | $14 |
| Dorzolamide-Timolol | 62 | $2,451 | $40 |
| Acetazolamide | 12 | $1,670 | $139 |
| Prednisolone Acetate | 17 | $1,051 | $62 |
| Timolol Maleate | 51 | $579 | $11 |
| Dorzolamide | 18 | $421 | $23 |
2018: 8 drugs
| Brimonidine | 50 | $7,823 | $156 |
| Azopt | 12 | $3,730 | $311 |
| Combigan | 12 | $1,890 | $157 |
| Latanoprost | 150 | $1,864 | $12 |
| Prednisolone Acetate | 15 | $659 | $44 |
| Dorzolamide-Timolol | 33 | $619 | $19 |
| Dorzolamide | 11 | $253 | $23 |
| Timolol Maleate | 22 | $196 | $9 |
2017: 6 drugs
| Brimonidine | 37 | $4,684 | $127 |
| Lumigan | 12 | $3,992 | $333 |
| Latanoprost | 71 | $1,018 | $14 |
| Dorzolamide-Timolol | 28 | $739 | $26 |
| Dorzolamide | 14 | $265 | $19 |
| Timolol Maleate | 12 | $99 | $8 |
2016: 8 drugs
| Brimonidine | 47 | $4,708 | $100 |
| Combigan | 23 | $3,917 | $170 |
| Travatan Z | 13 | $2,456 | $189 |
| Lumigan | 13 | $2,275 | $175 |
| Latanoprost | 56 | $761 | $14 |
| Dorzolamide-Timolol | 32 | $726 | $23 |
| Dorzolamide | 12 | $251 | $21 |
| Timolol Maleate | 24 | $188 | $8 |
2015: 7 drugs
| Lumigan | 38 | $5,137 | $135 |
| Brimonidine | 38 | $3,310 | $87 |
| Travatan Z | 12 | $2,668 | $222 |
| Combigan | 15 | $1,831 | $122 |
| Dorzolamide-Timolol | 29 | $909 | $31 |
| Latanoprost | 29 | $389 | $13 |
| Timolol Maleate | 30 | $252 | $8 |
2014: 6 drugs
| Brimonidine | 30 | $2,900 | $97 |
| Azopt | 12 | $1,852 | $154 |
| Dorzolamide-Timolol | 24 | $793 | $33 |
| Latanoprost | 24 | $422 | $18 |
| Erythromycin | 11 | $152 | $14 |
| Timolol Maleate | 13 | $118 | $9 |
2013: 2 drugs
| Brimonidine | 12 | $1,941 | $162 |
| Latanoprost | 17 | $319 | $19 |
Money from drug and device companies
$134 in 2025
| 2025 | 1 | 2 | None | $134 |
| 2024 | 4 | 10 | None | $311 |
| 2023 | 3 | 5 | None | $399 |
| 2022 | 5 | 7 | None | $321 |
| 2021 | 2 | 2 | None | $141 |
| 2019 | 3 | 4 | None | $275 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Hydrus Microstent | $134 | 2 payments
|
See all 2 published payments
| Alcon Vision | Meals · 2025-03-11 | Hydrus Microstent | $69 |
| Alcon Vision | Meals · 2025-02-13 | Hydrus Microstent | $65 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $311
| Alcon Vision | Clareon | $135 | 7 payments
|
| Glaukos | Idose | $83 | 1 payment
|
| Sight Sciences | Omni Surgical System | $68 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Simplicity | $24 | 1 payment
|
2023: $399
| Alcon Vision | Hydrus Microstent | $322 | 3 payments
|
| Sight Sciences | Omni Surgical System | $45 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $33 | 1 payment
|
2022: $321
| Sight Sciences | Omni(R) Surgical System (US) | $144 | 3 payments
|
| Alcon Vision | Acrysof Iq Panoptix Uv Iol | $51 | 1 payment
|
| Allergan | Xen Glaucoma Treatment System | $49 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $43 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $33 | 1 payment
|
2021: $141
| Alcon Vision | Acrysof Iq Panoptix | $117 | 1 payment
|
| Sight Sciences | Omni(R) Surgical System (US) | $25 | 1 payment
|
2019: $275
| Aerie Pharmaceuticals | Rhopressa | $148 | 1 payment
|
| Alcon Vision | Panoptix | $99 | 2 payments
|
| Sight Sciences | Omni | $29 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1215117296
- Licence
- CA A96850, IN 01068759A, MI 4301094206California A96850: Current · expires 2028-06-30
- Trained
- Washington University School of Medicine, 2004
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-11-07
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 900 Blake Wilbur Dr, Palo Alto, CA, 94304